"A recommendation in June 2020 from the High Blood Pressure Research Council (HBRCA) that
Australia’s Medical Services Advisory Committee (MSAC) and the Federal Minister for Health approve
reimbursement of ambulatory blood pressure monitoring (ABPM) through the country’s Medicare
Benefits Schedule (MBS) could increase demand for the Oscar 2 with SphygmoCor Inside ABPM in
Australia. The Oscar 2 is a 24-hour ambulatory blood pressure monitor (ABPM) by SunTech Medical
that includes the Company’s SphygmoCor® technology inside. This product is sold exclusively by ATCOR
in Australia.
HBRCA recommends that reimbursement be made available for diagnosis of hypertension in patients
who have measured clinic-based blood pressure between 140/90 mmHg and 180/110 mmHg, with
reimbursement up to once every 12 months for individuals who have not commenced
antihypertensive medication. The average recommended fee is A$107.60.
HBRCA estimates that more than 700,000 ABPM procedures will be required over the first three years
of coverage.
The Oscar 2 device adds ATCOR’s proprietary central blood pressure algorithms to a standard ABPM,
providing the benefits of central pressure waveform analysis for enhancement and individualization of
patient care over standard blood pressure monitoring."
This is a massive development!
It would be worth at least $200-$500m for the company's value
In the US we're only getting around US$20.00 under the CPT reimbursement code
That's mad news
CDX Price at posting:
3.6¢ Sentiment: Buy Disclosure: Held
